Atrium Therapeutics (RNA) Reiterated at Overweight by Cantor Fitzgerald After Model Update

October 15, 2026 7:51 AM

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $25.00 price target on Atrium Therapeutics (NASDAQ: RNA).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found